A lot has been written about ADC’s recently, and some of the most interesting revolved around the new Glaxo Smith Kline ADC GSK2857916. This drug has shown twice the the Overall Response Rate (ORR) than did Daratumumab as a single agent in clinical trial. GSK2057916 had a ORR of 60% and Darzalex had a 29% ORR. At the time 29% was a giant leap forward.Not to be left behind Daratumumab has been turned into a AWC(Anitbody Warhead Conjugate) by the biotech company Actinium Pharmaceuticals, Inc.(ATNM) This AWC showed a 10 fold improvement in myeloma cell death in vivo vs. Darzalex alone. Finally, Takeda has a new CD38 antibody called TAK-079 and they are partnering with the biotech Molecular Templates(MTEM) to manufacture what they call a ETB(Engineered Toxin Bodies). All use the same technique to link a toxin to an antibody with a linker.
Targeted therapy has been touted as the future of cancer treatment, but not until recently have we had such a rush of new developments. Large companies like GSK, Takeda, and Jannsen, small companies like Juno and Kite, and micro companies like Actinium, and Molecular Templates are changing the course of myeloma treatment more focused on the myeloma cancer cell target. If Cytoxin and Melphalan are the shotgun approach to cancer care, CAR T and ADC are the one shot one kill approach to care!